Purpose. The authors present a retrospective analysis of a large series of patients who underwent transjugular intrahepatic portosystemic shunt (TIPS) placement. Materials and methods. Between March 1992 and December 2006, 658 patients were referred to our centre for TIPS placement. Indications for the procedure were digestive tract bleeding (52.8%), refractory ascites (35.3%), preservation of portal vein patency prior to liver transplantation (3.0%) and thrombosis of the suprahepatic veins (2.3%). Other indications (6.6%) included pleural ascites, portal thrombosis and hepatorenal and hepatopulmonary syndromes. All patients were evaluated with colour Doppler ultrasonography and in a few cases with computed tomography. The portal system was punctured under sonographic guidance. Wallstent, Palmaz and Nitinol thermosensitive stents were used. Embolisation of persistent varices was performed in 6.8% of cases. Results. Technical success was 98.9%. During a 1,500-day follow-up, the cumulative incidence of stent revision was 25.7% (Nitinol), 32.9% (Wallstent) and 1.8% (Palmaz). Mortality rates were 31.1%, 38.5% and 56.4%, respectively. The technical complications included six cases of heart failure, six of haematobilia, three of stent migration, two of intrahepatic haematoma and one of haemoperitoneum. Eight patients with severe portosystemic encephalopathy (PSE) were treated with a reduction stent. 
Introduction
Transjugular intrahepatic portosystemic shunt (TIPS) insertion was introduced into clinical practice more than 20 years ago for the treatment of portal hypertension and its complications. A number of controlled trials have compared the efficacy of TIPS versus medical and endoscopic treatment in preventing variceal bleeding and treating refractory ascites, to date the universally accepted indications for TIPS [1] [2] [3] [4] [5] [6] [7] . Guidelines for the procedure have been established on the basis of technical angiographic aspects, clinical and laboratory prognostic factors and complication rate. Less common indications, some of which are not universally accepted, have been investigated by uncontrolled studies conducted on small patient series. These include portal thrombosis, Budd-Chiari syndrome, pleural ascites [8] [9] [10] , hepatopulmonary syndrome (HPS) [11] , hepatorenal syndrome (HRS) [3, [12] [13] [14] [15] [16] [17] , prophylaxis of intraoperative bleeding in cirrhotic patients with portal hypertension who are candidates for major abdominal surgery [8, 18, 19] and maintenance of portal vein patency prior to orthotopic liver transplantation (OLT) [20, 21] .
We retrospectively reviewed a large series of patients who underwent TIPS over a 15-year period at a referral centre and compared the data with the literature with the aim of providing useful radiological and clinical information for multidisciplinary management of cirrhotic patients with complicated portal hypertension.
Materials and methods
Between March 1992 and December 2006, 658 patients (432 males and 226 females, age range 4-85 years, mean age 56.2 years) with cirrhosis and portal hypertension of varying aetiology (Table 1) were referred to our centre for TIPS placement. The severity of the hepatic disease was judged according to the Child-Pugh classification: 18.9% patients were Child A, 55.9% were Child B, and 25.2% were Child C. Indications for TIPS placement are summarised in Table 2 . Fourteen patients had previously undergone liver transplantation and were being treated for portale e nel follow-up. La pervietà degli stent è soddisfacente.
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Introduzione
Da oltre 20 anni lo shunt intraepatico porto-sistemico (TIPS) è stato introdotto nella pratica clinica per il trattamento dell'ipertensione portale e delle sue complicanze.
Numerosi trials controllati hanno comparato l'efficacia della TIPS con la terapia medica ed endoscopica nella profilassi del sanguinamento da varici e nel trattamento dell'ascite refrattaria, che rimangono le principali indicazioni, univocamente condivise [1] [2] [3] [4] [5] [6] [7] ; le linee guida alla procedura sono state tracciate sulla base di aspetti tecnici angiografici, fattori prognostici clinico-laboratoristici ed incidenza di complicanze. Indicazioni più rare ed oggetto di studi non controllati condotti su piccoli gruppi di pazienti, alcune delle quali non uniformemente accettate sono: la trombosi portale, la sindrome di Budd-Chiari, l'ascite pleurica [8] [9] [10] , la sindrome epato-polmonare (HPS) [11] , la sindrome epato-renale (HRS) [3, [12] [13] [14] [15] [16] [17] , la profilassi del sanguinamento intraoperatorio in pazienti cirrotici con ipertensione portale candidati ad interventi di chirurgia addominale maggiore [8, 18, 19] e la tutela della pervietà portale pre-trapianto epatico (OLT) [20, 21] .
Scopo di questo lavoro è analizzare retrospettivamente, confrontandoli con una revisione della letteratura, i dati di un'ampia casistica di pazienti sottoposti a TIPS nell'arco di quindici anni presso un centro di riferimento al fine di fornire informazioni tecniche radiologiche e cliniche utili nella gestione multidisciplinare del paziente cirrotico con ipertensione portale complicata. refractory ascites (n=6), pleural ascites (n=4), bleeding (n=2) and recurrent Budd-Chiari syndrome (n=2).
Materiali e metodi
All patients referred electively to our centre had already undergone clinical assessment with echocardiography and portal ultrasonography (US). Computed tomography (CT) was performed to complete the diagnostic workup in 13 cases. A total of 149/658 patients (22.6%), including 24 emergency referrals, had had acute episodes of encephalopathy. Patients with chronic encephalopathy were not considered eligible for TIPS. TIPS procedures were performed in the angiography suite with the following X-ray systems: Angio Diagnost 3 DVI, Multi Diagnost 3 and Allura Xper FD20 (all Philips Medical Systems, Best, The Netherlands). In the case of elective procedures, patients signed the informed consent form and were assessed by an anaesthesiologist the day before the examination. All patients underwent complete blood count and coagulation screening tests and received broad-spectrum antibiotics.
Patients' vital signs were monitored continuously throughout the procedure, and an anaesthetist-resuscitator was present during all angiographic manoeuvres. After placing a 35-cm-long, 10-F vascular introducer in the internal jugular vein, the right (521 patients) or middle (128 patients) hepatic vein was cannulated with the aid of a 65-cm-long, 4-F angiographic catheter (Terumo Corporation, Tokyo, Japan) and a 180-cm-long, 0.035-in. J-tip hydrophilic guidewire (Terumo Corporation, Tokyo, Japan). The Terumo guidewire was then exchanged for a 180-cm-long. 0.035-in. J-tip Amplatz Super Stiff ST Teflon guidewire (Boston Scientific Corporation, Natick, MA, USA).
A 55-cm-long, 16-gauge, curved needle (Cook Europe, Bjaeverskov, Denmark) was introduced into the hepatic vein over the Teflon guidewire under fluoroscopic guidance, and more recently, the Rösch-Uchida portal access set (RUPS-100, Cook Europe) was used. US, performed with a 3.5-MHz convex-array probe and intercostal scans enabled us to withdraw the needle tip in the hepatic vein until a portal branch of adequate size and with favourable anatomical relationships could be identified, and subsequently to guide advancement of the obturator in real time. In two cases, the TIPS was created by directly puncturing the inferior vena cava because the hepatic veins could not be catheterised. In 520 cases, the portal system was accessed via the right portal vein, in 85 cases via the left portal vein and in 46 cases via the bifurcation.
After removing the needle obturator under US and fluoroscopic guidance, the hydrophilic guidewire was advanced to the portal trunk and a 110-cm-long, 4-F pigtail catheter was introduced into the guidewire. Portal (with the catheter tip in the trunk) and systemic (from the side of the vascular introducer sheath with the catheter tip in the hepatic vein) pressure measurements were then obtained, and subsequently portography was performed after injecting 25 ml of contrast material (Ultravist 370, Shering AG, Berlin, Germany) into the splenic vein at a flow rate of 8 ml/s with an automatic injector. The parenchymal tract was then dilated until complete distension by using an 8-mm angioplasty balloon catheter of varying length (4-8 cm) (Wanda, Boston Scientific, Natick, MA, USA; Smash, Boston Scientific; XXL, Boston Scientific). Both portal-vein puncture and dilation of the tract were carried out after adequate sedation (Remifentanil 0.05-0.1 γ kg/min and Propofol 1 mg/kg per hour). Subsequently, the Palmaz (mechanically expandable), Memotherm and Luminexx (nitinol), Wallstent and Wallgraft (self-expandable) stents (Table 3) In 45 pazienti (6,8%) , di cui 15 sottoposti a TIPS in regime d'urgenza, si è deciso di eseguire l'embolizzazione selettiva di varici gastro-esofagee persistenti con spirali repeated angioplasty procedures using 8-to 14-mm balloons. Attempts at fibrinolysis with Urokinase (200,000 IU as a bolus followed by 1 million IU over 24 h) were ineffective.
Finally, postprocedural phlebography was performed with the flow rates described above, and the new portal and systemic pressures were measured: exclusive opacification of the main intrahepatic portal branches and variceal devascularisation at portography along with a portosystemic gradient ≤10 mmHg were considered evidence of haemodynamic success.
In 45 patients (6.8%), 15 of whom were emergency referrals, we decided to perform selective embolisation of persistent gastro-oesophageal varices with metal coils (Balt, Montmorency, France; Cook Europe) measuring 10 mm and 16 mm in diameter. Technical success was defined as correct position and regular stent patency, with rapid opacification of the right atrium at phlebography. In seven patients, TIPS placement could not be completed owing to chronic occlusion of the hepatic veins due to intrahepatic progression of portal thrombosis or because of unfavourable anatomical relationships between the portal and hepatic veins.
Within 48 h of the angiographic procedure, abdominal US was carried out to exclude any possible complications. In one case of recurrent early occlusion of TIPS, stent patency was achieved by inserting an additional 12-mmcalibre covered stent coaxially to the previously deployed stents (Wallgraft, Boston Scientific).
Patients subsequently underwent US every 6 months, or more frequently if clinically indicated. Shunts with a flow rate <800 ml/min were eligible for angiographic revision. Clinical success was assessed on the basis of gastroenterological examinations, abdominal US, oesophagogastroduodenoscopy and laboratory tests; a time interval of 6 months after the procedure was considered in order to reduce the influence of many variables (progression of cirrhosis-related liver failure, comorbidity, etc.).
The cumulative incidence of reoperation on the different stents utilised and patient survival were assessed with the Gooley method [22] on 307/658 subjects with long-term follow-up (1,500 days) carried out with a standard protocol at our hospital. The Gray test was used to compare the cumulative incidences [23] . Our analysis did not consider the remaining 351 patients, for whom follow-up was limited and not performed, according to a standard protocol.
Results
Technical and haemodynamic success was achieved in 651/658 cases (98.9%). The cumulative incidence of reoperation was very similar for the Nitinol stents [25.7%, 19.2%-32% with a 95% confidence interval (CI)] and selfexpandable stents (32.9%, 18.9%-46.8% with a 95% CI), whereas it was substantially lower (1.8%, 0%-5.3% with a 95% CI) for the Palmaz stents (Fig. 1) . In patients treated for hepatic vein thrombosis or hepatopulmonary syndrome, the stent had to be revised within the first year after insertion in 40% and 66.7% of cases, respectively. Fig. 1 also shows that mortality was high, with deaths occurring early after stent placement (56.4%, 43.9%-68.7% with a 95% CI) among patients treated with Palmaz stents, whereas it was lower, with deaths more evenly distributed over time, among those treated with the thermosensitive (31.1%, 24.2%-37.8% with a 95% CI) and self-expandable (38.5%, 20.8%-56% with a 95% CI) stents.
Clinical success, considering that 51 patients proceeded to OLT on average 6 months after TIPS placement, was achieved in 100% of patients with portal thrombosis (ascites regression and variceal devascularisation) or candidates for gastrectomy (no substantial intraoperative haemorrhage); 91% of cases of bleeding (haemodynamic stability), considering that 19/76 (25%) emergency referrals died within 30 days of TIPS, 60% of patients with refractory ascites (minimal or absent ascites, mild diuretic therapy and no paracentesis), 70% of patients with HRS (discontinuation of haemodialysis and improved serum creatinine), 65% of cases of pleural ascites (increased respiratory volumes and improved ventilation), 47% of cases of Budd-Chiari syndrome (regression of ascites with significant reduction of liver volume) and 20% of patients with HPS (significant increase in oxygen saturation).
None of the procedure-related complications proved fatal or required surgical repair. The following complications occurred: heart failure due to right-sided overload (n=6), haematobilia (n=6), accidental migration of Palmaz stent into the pulmonary artery (n=3), intrahepatic
significativa riduzione volumetrica del fegato) e nel 20% dei pazienti con HPS (incremento significativo della saturazione di ossigeno).
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Days from TIPS haematoma (n=2) and haemoperitoneum (n=1). The migrated stents were dilated in branches of the pulmonary artery. The cases of right-sided heart failure, two of which were severe, were successfully treated with medical therapy. Intraparenchymal haematomas, occurring in heavily anticoagulated patients -perhaps due to accidental puncture of arterial branches -gave rise to no specific symptoms or anaemia, were diagnosed on early postprocedural abdominal US and resolved spontaneously. The case of haemoperitoneum occurred within hours of an emergency TIPS procedure owing to extravasation of a persisting nonembolised gastric varix in the presence of an endoscopic haemostatic device. The clinically suspected complication was confirmed by CT and treated with selective coil embolisation. The six cases of haematobilia were caused by accidental puncture of the gall bladder or highorder bile duct branches and were diagnosed on US within 24 h of the procedure; 3/6 patients received blood transfusion. Portosystemic encephalopathy (PSE) developed following TIPS in 77/651 patients (11.8%), with an incidence that was particularly high among patients with pleural ascites (4/12 patients, 33.3%). Eight patients with severe encephalopathy were treated with a 14 × 40-mm reduction stent (Sinus-Reduzier-Stent, OptiMed, Ettlingen, Germany). In 43/651 patients (6.6%) treated for bleeding or refractory ascites, PSE resolved following the TIPS procedure.
Discussion
Clinical aspects
In our experience, oesophageal, gastric and intestinal bleeding is the most frequent indication for TIPS placement. Riguardo all'impiego della TIPS nel trattamento early deaths among emergency referrals, 80% of whom, however, would have died in any case due to uncontrolled bleeding [29] . Refractory ascites, correlated to poor outcome and increased risk of infection and kidney failure [30] , was the second leading indication for TIPS in our series. The clinical outcome of TIPS, in our experience and that of other authors [31] , is unrelated to liver function at baseline, and no certain positive prognostic factors have been identified to date.
With regard to the use of TIPS in the treatment of hepatic hydrothorax, our results were similar in terms of clinical outcome [32, 33] and PSE incidence with those of other nonrandomised, uncontrolled studies [34] . In many cases, TIPS placement serves as a "bridge" to OLT, without which these patients die mainly of complications related to liver failure progression [35] .
Published studies have demonstrated that only a minority of patients with HRS can benefit from TIPS; many patients with HRS I die within 3 months of the diagnosis, whereas others affected by HRS II and severe liver failure die unless timely transplantation occurs. Alcohol-induced cirrhosis with relatively preserved liver function has a better prognosis.
In candidates for OLT, TIPS creation ensured portal patency. Because the waiting list for OLT is relatively short at our hospital (6 months on average), it was jointly decided to dilate the stent to 8 mm only in order to reduce the risk of liver failure. There is evidence that TIPS may reduce the mortality and morbidity associated with OLT [21] .
No randomised controlled trials exist that establish a protocol for the treatment of Budd-Chiari syndrome. Treatment decisions are dependent on cause, age and extent of thrombosis. In patients unresponsive to anticoagulation therapy, TIPS can reduce portal hypertension, improve liver function and control ascites [3] .
The only established treatment for HPS is liver transplantation, which may, however, be risky or contraindicated in cases of severe hypoxaemia [11] . The therapeutic efficacy of the intrahepatic shunt is still controversial, with some authors suggesting that the extent of arteriovenous pulmonary fistulas before treatment and the portosystemic gradient after TIPS are the main determinants of outcome. The unsatisfactory clinical impact observed in out series may be explained by the comorbidities affecting some of our patients (two cases of emphysema, one of a previous specific process), whereas we are unable to account for the high incidence of stent revisions.
In our patients who received lactulose to regulate bowel function, the PSE induced by TIPS was mostly transient and mild to moderate and rarely required an angiographic reduction procedure. PSE regression following TIPS in patients treated for bleeding or intractable ascites may be explained dell'idrotorace epatico il nostro studio si allinea per risultato clinico [32, 33] by discontinued intestinal absorption of blood proteins and by a significant reduction of diuretic treatment, respectively.
The cases of right-sided cardiac failure following TIPS induced us to perform echocardiography on all candidates for the procedure.
Technical aspects US enabled correct patient selection, was effective in guiding the portal puncture and helped to avoid major periprocedural complications [36] . The cases of intraparenchymal haematoma and haematobilia occurred at the end of particularly complex procedures, and their onset was promoted by the blood dyscrasia typical of cirrhosis.
Pre-TIPS radiological assessment, in some cases supplemented by a CT study, provides essential information about the nature, extent and age of the portal thrombus and on the haemodynamics of the splenomesenteric system.
Our experience confirms previously reported findings [37] regarding the greater technical difficulty of angiographic procedures, sometimes requiring transcaval puncture, and the high incidence of occlusions at 1 year when patients with Budd-Chiari syndrome are treated with bare stents. This finding suggests that US should be performed more frequently -every 3-4 months.
The case of haemoperitoneum emphasises the need for accurate phlebography following TIPS, with injection of contrast material into the proximal splenic vein in order to demonstrate any persistent varices.
In our experience, the patency of self-expandable and thermosensitive bare stents was satisfactory but lower than that of modern polytetrafluoroethylene (PTFE)-covered stents [38] . The performance of nitinol stents and selfexpandable stents was identical, and their mortality rate was similar. The cumulative incidence of revision of Palmaz stents was low only because the mortality associated with their use was very high. This type of stent-graft, which has inherent technical limitations, was used in the early years of our experience and was characterised by less accurate patient selection, less technical skill of the interventional radiologists' and organisational problems in referring patients for OLT.
Conclusions
TIPS placement is a safe and effective first-line procedure to treat complications of portal hypertension that are refractory to medical and endoscopic therapy. Indication for the procedure must be established jointly by the gastroenterologist and the interventional radiologist. Pre-TIPS assessment involves both clinical and laboratory investigations (liver and kidney function) and imaging studies (US and, in Il confezionamento dello shunt rappresenta una tra le procedure radiologiche interventistiche più complesse, che si giova dell'ecografia come metodica guida principe alla selected cases, CT).
Shunt creation is among the most complex interventional radiology procedures, and it relies on US to guide the portal puncture. After stent implantation, the patient requires periodic US follow-up examinations to enable early detection of shunt malfunction. The literature indicates that modern covered stents ensure better primary patency than do bare stents and that their higher cost is offset by the fewer angiographic revisions required during the follow-up.
Although there is consensus regarding the effectiveness of TIPS in treating variceal bleeding, refractory ascites and hydrothorax -despite the increased incidence of PSEthere is still controversy about the use of TIPS to treat rarer and more complex conditions, such as Budd-Chiari syndrome, HRS and HPS.
Finally, in some patients, TIPS can serve as an effective bridge to OLT. In these cases, the waiting times of the transplant centre will affect the indications and technical aspects of the procedure. 
